Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Eli Lilly

Eli Lilly starts website to connect patients with new obesity treatment, Zepbound, other drugs

Eli Lilly has launched a unique website to connect U.S. patients seeking obesity treatment to doctors, dieticians and its new weight-loss drug, Zepbound

The Independent UK

Eli Lilly Launches Unique Website Connecting Patients to Obesity Care+

Eli Lilly launches LillyDirect, a one-of-a-kind website connecting patients seeking obesity treatment to doctors and its weight-loss drug. Streamlining hea...

Top News

Eli Lilly cracks down on the use of weight loss drugs Mounjaro and Zepbound for ‘cosmetic’ reasons instead of diabetes and obesity

The news comes as rampant demand for the reputed “miracle drugs” leads to nationwide shortages.

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

Eli Lilly Stock: Buy or Sell?

Eli Lilly's diversified portfolio and high demand for its weight-loss drugs have pushed it to the top of Wall Street's list of top pharma stocks for 2024. Is now the time to buy?

Barchart

Insulin Now Available for $35 a Month for Many Americans

Insulin price caps from Eli Lilly, Novo Nordisk and Sanofi take effect this month.

Kiplinger

Weight loss from Lilly’s Zepbound drug reversed after stopping treatment, according to study

‘They gain back about half the weight they had originally lost over a one-year period of time,’ professor says

The Independent UK

Which Weight Loss Drug Is Best And Safest? Here’s What Sets Them Apart

Earlier this month, the FDA approved Eli Lilly's Zepbound, a drug similar to its diabetes drug Mounjaro but specifically advertised for weight loss.

Inverse

Read news from The Economist, FT, and more,
with one subscription

Chasing Weight Loss Dream, Many In US Seek Ozempic Alternatives

Like many Americans struggling to lose weight, Marissa Montanino felt compelled to try Ozempic or one of the other new so-called "wonder drugs" described as revolutionary in the fight against obesity.

International Business Times

Pfizer nixes more study of twice-daily obesity pill treatment that made many patients nauseous

Pfizer shares sank Friday when the drugmaker announced that it was abandoning a twice-daily obesity treatment after more than half the patients in a clinical trial stopped taking it

The Independent UK

Eli Lilly’s CFO explains why the company’s newest weight-loss drug Zepbound will cost 20% less than the current options

Zepbound is expected to be available in the U.S. by the end of the year.

Fortune

Will Weight Loss Drugs be the Next Big Thing?

Several pharmaceutical companies are racing to develop obesity drugs and tap into a surge in consumer demand for the extremely profitable drugs. Sales of Eli Lilly’s (LLY ) diabetes drug Mounjaro, just approved by the U.S. Food and Drug Administration (FDA) for obesity in the U.S., hit $1.41 billion in...

Barchart

Novo Nordisk faces first real test as Eli Lilly wins approval for a weight loss-aiding drug

U.S. regulators signed off on Eli Lilly’s diabetes drug Zepbound, which can also be used to aid weight loss like Wegovy and Ozempic.

Fortune

AstraZeneca makes big push into weight-loss market with obesity pill deal

UK drugmaker signs agreement with China’s Eccogene to work on an obesity and type 2 diabetes pill

The Guardian - UK

Novo Nordisk isn’t alone: Sales of Wegovy rival Mounjaro explode as drugmaker Eli Lilly profits from Americans’ weight-loss craze

Drugs helping weight-loss like Novo Nordisk's Wegovy and Eli Lilly's Mounjaro drove blockbuster sales for the pharma giants in the third quarter.

Fortune

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Stock Index Futures Climb on Hopes of End to Fed Rate Hikes, Apple Earnings on Tap

December S&P 500 futures (ESZ23) are up +0.50%, and December Nasdaq 100 E-Mini futures (NQZ23) are up +0.70% this morning as market participants weighed the possible peak of the Federal Reserve’s historic tightening campaign and looked ahead to an earnings report from Apple.

Barchart

Chart of the Day: Eli Lilly - Big Profits in Big Pharma

The Chart of the Day belongs to the pharmaceutical giant Eli Lilly (LLY) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum and having a Trend Seeker buy signal then used the Flipchart...

Barchart

Is It Too Late To Buy Eli Lilly Stock?

Eli Lilly stock has crushed the broader markets in the past 10 years. But should you buy LLY at current levels, given its lofty valuation?

The Independent UK

Drug used in diabetes treatment Mounjaro helped dieters shed 60 pounds, study finds

A new study finds that the medicine in the diabetes drug Mounjaro helped people with obesity or who are overweight lose at least a quarter of their body weight

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - US

US nutrition panel’s ties to top food giants revealed in new report

Transparency group US Right to Know finds members linked to Nestlé, Coca-Cola and others, raising conflict-of-interest questions

Barchart

Here's What $1,000 Invested in Eli Lilly 10 Years Ago Would Be Worth Now

Eli Lilly stock has surged over 1,200% in the last 10 years. Here's why I remain bullish on this blue-chip healthcare stock right now.

The Conversation

Mounjaro: type 2 diabetes drug more effective than Ozempic to launch in the UK — here’s what you need to know

A new drug to treat type 2 diabetes has been approved for use) in the UK. Tirzepatide (sold under the brand name Mounjaro) could be available for prescription by early 2024 – subject to availability.

The Guardian - UK

Wegovy: the slimming drug that keeps Denmark’s economy growing

Novo Nordisk, the maker of the blockbuster obesity injection, has singlehandedly saved the country from recession

The Independent UK

Another weight loss jab approved for NHS use

The once-weekly jab was hailed as a ‘much-needed addition to other available treatments’

The Independent UK

Weight loss jab recommended to treat type 2 diabetes

The once-weekly jab was hailed as a ‘much-needed addition to other available treatments’

Barchart

Chart of the Day: Eli Lilly (LLY) Edges to New Record High

The Barchart Chart of the Day belongs to Eli Lilly (LLY) . I found the stock by using Barchart.com to find the "Barchart New Highs" page, and then I clicked on pull-down to select stocks with new 52-week highs. I then viewed the stocks on the list with the FlipCharts...

1 … 20 21 22 23

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.